ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Other Events
Item 8.01. Other Events.
On April 3, 2019, Alimera Sciences, Inc. (the “Company”) appointed Samer Kaba, MD, as the Company’s Chief Medical Officer, effective April 4, 2019. Dr. Kaba is responsible for directing the Company’s global medical strategy behind current and future projects. Functions under Dr. Kaba’s oversight will include medical affairs, pharmacovigilance, medical information, quality, clinical operations, and regulatory.
On April 4, 2019, the Company issued a press release announcing the appointment of Dr. Kaba as described above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 8.01. Financial Statements and Exhibits.
(d)Exhibits
ALIMERA SCIENCES INC Exhibit
EX-99.1 2 pr.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE For press inquiries:Katie Brazelfor Alimera Sciences [email protected] investor inquiries:Rich CockrellCG Capitalfor Alimera [email protected] Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba,…
To view the full exhibit click here
About ALIMERA SCIENCES, INC. (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
